X-Zell
Early, pain-free cancer detection.
X-Zell is active in the healthcare space based in Singapore, Singapore; Bangkok, Thailand; Düsseldorf, NRW, Germany, founded in 2018.
Profile
X-ZELL™ is a global start-up specialising in rare cell detection technology.
Backed by Y Combinator and various high-profile angel investors from around the globe – among them Gmail creator Paul Buchheit – X-ZELL™ has developed a world-first platform technology capable of isolating and visualizing rare and abnormal cells such as Circulating Endothelial Cells (CEC).
X-ZELL™’s platform technology is based on four core modules covering the entire spectrum from blood processing through to cell analysis and reporting – with every step performed in-house using patented and proprietary technology.
By combining the wisdom of 4,000 years of pathologic research with X-ZELL™’s own, cutting-edge technology,
X-ZELL™ ensures robust results and maximum clinical utility across a broad range of medical applications – from research through to medication management, companions diagnostics, relapse control and diagnostic decision-making.
More information on www.x-zell.com and @XZELLInc
X-Zell is positioned in healthcare, a segment that rewards a clear, focused offering.
Singapore, Singapore; Bangkok, Thailand; Düsseldorf, NRW, Germany is where the company is located.
It is recorded at the Winter 2015 stage.
The company reports a headcount in the 19 range.
Directory analysis
X‑Zell is a healthcare startup that builds a proprietary platform for detecting rare and abnormal cells in blood, such as circulating endothelial cells. The system integrates blood processing, cell isolation, imaging, and reporting in a single, in‑house workflow. It aims to deliver early, pain‑free cancer detection and other diagnostic applications.
Positioning: X‑Zell targets the liquid biopsy niche, offering a unique end‑to‑end platform that could set it apart from conventional lab‑based diagnostics. The company is early stage with limited disclosed funding, relying on Y Combinator support and high‑profile angel investors.
Note: X‑Zell’s platform claims to isolate and visualize rare cells directly from a blood sample.
Auto-generated directory analysis from public data · updated 6 Oct 2026. Informational only, not investment advice.
| Sector | Healthcare |
|---|---|
| Headquarters | Singapore, Singapore; Bangkok, Thailand; Düsseldorf, NRW, Germany |
| Country | Germany |
| Founded | 2018 |
| Employees | 19 |
| Stage | Winter 2015 |
Website: www.x-zell.com
Browse related
Create a free account